论文部分内容阅读
为验证拉莫三嗪治疗儿童癫痫的疗效和安全性,对44例儿童顽固性癫痫进行了开放性自身对照研究。以治疗前3个月的发作频度为基础,治疗后观察3个月。结果:发作频率减低≥50％的患儿占54.5％(24/44例),拉莫三嗪对各型发作均有效,其中全身强直一阵挛型或Lennox-Gastaut综合征者疗效最佳。拉莫三嗪耐受性较好,偶有复视、呕吐、头晕等副反应。提示拉莫三嗪是一种治疗儿童癫痫的有效、广谱、低毒的抗癫痫药。
To verify the efficacy and safety of lamotrigine in the treatment of children with epilepsy, 44 children with intractable epilepsy were enrolled in an open-label, self-controlled study. Based on the frequency of seizures in the first 3 months of treatment, they were observed for 3 months after treatment. Results: Lamivudine was effective in all kinds of attacks in 54.5% (24/44 cases) of children with ≥50% reduction of seizure frequency. Among them, systemic tonic-type or Lennox-Gastaut syndrome were the best. Lamotrigine is better tolerated, occasional diplopia, vomiting, dizziness and other side effects. It is suggested that lamotrigine is an effective, broad-spectrum and low-toxicity antiepileptic drug for children with epilepsy.